Led · Series B · Aug 2026

InduPro uses a proprietary proximity-guided platform to map spatial organization of proteins on the cell surface and discover selective co-target pairs for therapeutic development. Its lead program, IDP-001, is a potential first-in-class proximity-based bispecific antibody-drug conjugate targeting EGFR and a novel Tumor-Associated Proximity Antigen (TAPA-E1). IDP-001 was designed to enhance tumor selectivity, target internalization, and antitumor efficacy while aiming to preserve tolerability, and the first patient has been dosed in its Phase 1 study. The Phase 1 trial is enrolling adults with advanced or metastatic squamous and non-squamous non-small cell lung cancer and other squamous solid tumors to evaluate safety, pharmacokinetics and preliminary antitumor activity. Beyond ADCs, InduPro is developing bispecific antibodies including antibody-drug conjugates and T-cell engagers to build a pipeline of first- and best-in-class programs. The company operates out of Seattle and Cambridge, Mass., and is advancing both clinical and preclinical programs supported by venture and strategic pharma investors.

Led · Series B · Jun 2026

Nura Bio is a clinical-stage biopharmaceutical company focused on developing small molecule neuroprotective therapies that halt axon degeneration by inhibiting SARM1. Its lead programs include NB-4746, a first-generation oral, brain-penetrant reversible orthosteric SARM1 inhibitor currently in a Phase 1b/2a global ALS study, and NB-9402, a second-generation oral covalent irreversible allosteric SARM1 inhibitor in a Phase 1a first-in-human study. NB-4746 demonstrated a favorable safety profile and achieved target plasma and cerebrospinal fluid exposure in a Phase 1 study in healthy volunteers, and preclinical studies支持 neuroprotection across central, peripheral, and ocular nervous system models. The company intends to use proceeds from its recently completed $73.8M Series B to fund clinical proof-of-biology studies and advance its clinical pipeline. Nura Bio is based in South San Francisco and is positioning a portfolio of differentiated SARM1 inhibitors to explore therapeutic potential across multiple neurological diseases.

Participated · Seed · Apr 2026

Tortugas Neuroscience is a clinical-stage, neurology-focused biotech led by CEO Jeff Jonas and based in Framingham, MA. Its pipeline, in-licensed from Eisai Co., Ltd. and Jiangsu Hansoh Pharmaceutical Group Ltd., includes potential treatments for schizophrenia, tinnitus, focal epilepsy, reversible encephalopathies and other CNS indications. Programs center on small-molecule new chemical entities with derisked mechanisms of action designed as once-daily oral formulations with differentiated pharmacological profiles and indication-expansion potential. The company is advancing two lead candidates through Phase 2 clinical trials. The recent $106M Seed and Series A financings are intended to support ongoing research and development and completion of those Phase 2 studies.

Participated · Series B · Mar 2026

Atavistik Bio is advancing a lead program, ATV-1601, an oral AKT1-selective inhibitor being developed as a potential treatment for hereditary hemorrhagic telangiectasia (HHT), a rare genetic bleeding disorder with no approved therapies. The company is also developing a JAK2 V617F mutant-selective inhibitor for myeloproliferative neoplasms, a group of chronic blood cancers. The recent Series B extension increases available capital to support clinical development of ATV-1601 and further advancement of the JAK2 inhibitor. Atavistik previously announced a $120 million Series B in December 2025, and the extension brings total Series B proceeds to $160 million. Leadership has signaled the new funding will accelerate development toward improved efficacy and tolerability for patients, according to CEO Bryan Stuart.

Led · Series A · Oct 2025

Nilo Therapeutics is a biotechnology startup leveraging discoveries at the nexus of neuroscience and immunology to create therapeutics that centrally modulate immune responses. Its lead concept targets vagal neurons that orchestrate systemic inflammation, offering an alternative to broad immunosuppression by restoring immune homeostasis through coordinated pathway control. This approach is intended to reduce therapeutic resistance and unlock treatment options across a wide range of autoimmune and inflammatory disorders with high unmet need. The science originates from founders Charles Zuker (Columbia), Ruslan Medzhitov (Yale), and Steve Liberles (Harvard) and was incubated with The Column Group. Fresh out of stealth, the company is building laboratories in New York City and expanding an interdisciplinary R&D team. A $101 million Series A financing will fund these efforts and advance the company’s preclinical programs. Nilo has not yet disclosed commercial products, revenue, or user metrics.